(secondQuint)SU5416 in Treating Patients With Advanced or Recurrent Cancer of the Head and Neck.

 OBJECTIVES: - Determine the effect of SU5416 on survival and tumor response in patients with advanced or recurrent squamous cell carcinoma of the head and neck.

 - Determine the safety and toxicity of SU5416 in these patients.

 OUTLINE: Patients receive SU5416 IV over 1 hour twice weekly.

 Treatment continues in the absence of disease progression or unacceptable toxicity.

 Patients are followed for 1 year.

 PROJECTED ACCRUAL: A total of 35 patients will be accrued for this study within 1.

4 years.

.

 SU5416 in Treating Patients With Advanced or Recurrent Cancer of the Head and Neck@highlight

RATIONALE: SU5416 may stop the growth of cancer cells by stopping blood flow to the tumor.

 PURPOSE: Phase II trial to study the effectiveness of SU5416 in treating patients who have advanced or recurrent cancer of the head and neck.

